Search Results

Your search for antibody drug conjugates matches 252 pages

Showing 251 - 252

By The ASCO Post Staff / Monday, April 8, 2013 4:28 PM

Biomarker Analysis Identified Women Most Likely to Benefit from T-DM1

For women with metastatic, HER2-positive breast cancer, the amount of HER2 on their tumor might determine how much they benefit from T-DMI—also now known as ado-trastuzumab emtansine (Kadcyla)—according to data from a subanalysis of the phase III clinical trial that led the FDA to...

gynecologic cancers

By The ASCO Post Staff / Monday, April 8, 2013 10:15 AM

New Type of Experimental Drug Active in Platinum-resistant Ovarian Cancers

The antibody-drug conjugate DMUC5754A, a novel member of a relatively new class of drugs, showed activity in women with ovarian cancer, even those with hard-to-treat, platinum-resistant disease, in a phase I trial presented at the AACR Annual Meeting 2013, held in Washington, DC, April 6 to 10....

Apr

Today In Oncology

Search Results

Your search for antibody drug conjugates matches 252 pages

Biomarker Analysis Identified Women Most Likely to Benefit from T-DM1

New Type of Experimental Drug Active in Platinum-resistant Ovarian Cancers

Small Phase II Study Examines Triplet Regimen for Patients With HER2-Positive Breast Cancer and Leptomeningeal Metastasis

Long-Term Outcomes With Pralsetinib in RET Fusion–Positive NSCLC

IMPT vs IMRT in Oropharyngeal Cancer

Metastatic Papillary Renal Cancer Final Results With Savolitinib and Durvalumab

Damaging Missense Variants in Innate Immunity Genes Linked to Earlier Breast Cancer Onset in BRCA1 Carriers